étaient représentés par l'hypotension (24,8%) et les vomissements (6,5%) ,
4%) patients selon les études) ; les taux d'arrêt dans notre travail sont plus faibles puisque la situation se, 5%) à quatre ,
Prise en charge de l???art??riopathie chronique oblit??rante ath??roscl??reuse des membres inf??rieurs, Journal des Maladies Vasculaires, vol.31, issue.4, pp.206-223, 2006. ,
DOI : 10.1016/S0398-0499(06)76545-3
Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care, JAMA, vol.286, issue.11, pp.1317-1324, 2001. ,
DOI : 10.1001/jama.286.11.1317
Determinants of Peripheral Arterial Disease in the Elderly, Archives of Internal Medicine, vol.160, issue.19, pp.2934-2938, 2000. ,
DOI : 10.1001/archinte.160.19.2934
High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study, Atherosclerosis, vol.172, issue.1, pp.95-105, 2004. ,
DOI : 10.1016/S0021-9150(03)00204-1
Assessment of the prevalence of atherosclerotic lower limb arteriopathy in France as a systolic index in a vascular risk population], J Mal Vasc. févr, vol.25, issue.1, pp.38-46, 2000. ,
Livre blanc sur la prise en charge des maladies cardiovasculaires en France, 2000. ,
ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases, Endorsed by: the European Stroke Organisation, pp.2851-2906, 2011. ,
DOI : 10.1016/j.rec.2011.11.007
URL : https://hal.archives-ouvertes.fr/hal-00678704
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), Journal of Vascular Surgery, vol.45, issue.1, pp.5-67, 2007. ,
DOI : 10.1016/j.jvs.2006.12.037
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults, Journal of the American College of Cardiology, vol.56, issue.25, pp.50-103, 2010. ,
DOI : 10.1016/j.jacc.2010.09.001
Association of low ankle brachial index with high mortality in primary care, European Heart Journal, vol.27, issue.14, pp.1743-1749, 2006. ,
DOI : 10.1093/eurheartj/ehl092
International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis, JAMA, vol.295, issue.2 ,
DOI : 10.1001/jama.295.2.180
Peripheral Arterial Disease as an Independent Predictor for Excess Stroke Morbidity and Mortality in Primary-Care Patients: 5-Year Results of the getABI Study, Cerebrovascular Diseases, vol.29, issue.6, pp.546-554, 2010. ,
DOI : 10.1159/000306640
The Long-term Prognostic Value of the Resting and Postexercise Ankle-Brachial Index, Archives of Internal Medicine, vol.166, issue.5, pp.529-535, 2006. ,
DOI : 10.1001/archinte.166.5.529
Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes, Circulation, vol.107, issue.5, pp.753-756, 2003. ,
DOI : 10.1161/01.CIR.0000049640.46039.52
Chapter I: Definitions, Epidemiology, Clinical Presentation and Prognosis, European Journal of Vascular and Endovascular Surgery, vol.42, issue.2, pp.4-12, 2011. ,
DOI : 10.1016/S1078-5884(11)60009-9
URL : http://doi.org/10.1016/s1078-5884(11)60009-9
Standards de qualit?? pour la pratique des examens Doppler et ??cho-Doppler art??riel des membres inf??rieurs en m??decine vasculaire. Rapport de la Soci??t?? fran??aise de m??decine vasculaire (SFMV), Journal des Maladies Vasculaires, vol.36, issue.6, pp.364-385, 2011. ,
DOI : 10.1016/j.jmv.2011.10.002
guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation, National Heart, Lung, and Blood J Am Coll Cardiol, vol.2147, issue.6, pp.1239-1312, 2005. ,
Measurement and Interpretation of the Ankle-Brachial Index: A Scientific Statement From the American Heart Association, Circulation, vol.126, issue.24, pp.2890-2909, 2012. ,
DOI : 10.1161/CIR.0b013e318276fbcb
URL : https://hal.archives-ouvertes.fr/hal-00921590
2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation. 1 nov, vol.124, issue.18, pp.2020-2045, 2005. ,
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), CAPRIE Steering Committee. Lancet. 16 nov, vol.348, issue.9038, pp.1329-1339, 1996. ,
A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb, European Journal of Vascular Surgery, vol.4, issue.5, pp.463-467, 1990. ,
DOI : 10.1016/S0950-821X(05)80784-4
Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative], Schweiz Med Wochenschr. 6 oct, vol.120, issue.40, pp.1477-1482, 1990. ,
Iloprost, ein stabiles Prostacyclinderivat, bei arterieller Verschlu??krankheit im Stadium IV: Eine placebo-kontrollierte Multizenterstudie, DMW - Deutsche Medizinische Wochenschrift, vol.114, issue.20, pp.783-788, 1946. ,
DOI : 10.1055/s-2008-1066673
Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost, Int Angiol J Int Union Angiol. déc, vol.10, issue.4, pp.229-232, 1991. ,
Thromboangiitis Obliterans (Buerger's Disease), New England Journal of Medicine, vol.343, issue.12, pp.864-869, 2000. ,
DOI : 10.1056/NEJM200009213431207
Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist, Rheumatology, vol.46, issue.2, pp.192-199, 2007. ,
DOI : 10.1093/rheumatology/kel388
Buerger's disease or thromboangiitis obliterans]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, janv, vol.19, issue.1, pp.34-43, 1998. ,
Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease), Journal of the American College of Cardiology, vol.44, issue.12, pp.2410-2411, 2004. ,
DOI : 10.1016/j.jacc.2004.09.029
Thromboangiitis obliterans in the 21st century???A new face of disease, Atherosclerosis, vol.206, issue.2, pp.328-334, 2009. ,
DOI : 10.1016/j.atherosclerosis.2009.01.042
The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease), Circulation. nov, vol.82, issue.5, 1990. ,
Thromboangiitis obliterans (Buerger??s disease), Current Opinion in Rheumatology, vol.18, issue.1, pp.18-24, 2006. ,
DOI : 10.1097/01.bor.0000198000.58073.aa
The Role of Prothrombotic Mutations in Patients with Buerger's Disease, Thrombosis Research, vol.100, issue.3, pp.143-147, 2000. ,
DOI : 10.1016/S0049-3848(00)00310-8
Prothrombotic Risk Factors in Patients with Thrombangitis Obliterans, Thrombosis Research, vol.99, issue.5, pp.483-486, 2000. ,
DOI : 10.1016/S0049-3848(00)00266-8
Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans ??? current practices, International Journal of Angiology, vol.18, issue.03, p.119, 2009. ,
DOI : 10.1055/s-0031-1278337
A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease, Int Angiol J Int Union Angiol. juin, vol.25, issue.2, pp.162-168, 2006. ,
Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans, The Lancet, vol.335, issue.8689, pp.555-557, 1990. ,
DOI : 10.1016/0140-6736(90)90346-7
A Stable Prostacyclin Analogue (Iloprost) in the Treatment of Buerger's Disease: A Prospective Analysis, p.150 ,
Ann Thorac Cardiovasc Surg Off J Assoc Thorac Cardiovasc Surg Asia, 2012. ,
Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis & Rheumatism, vol.132, issue.12, pp.3985-3993, 2004. ,
DOI : 10.1002/art.20676
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial, Annals of the Rheumatic Diseases, vol.70, issue.1, pp.32-38, 2011. ,
DOI : 10.1136/ard.2010.130658
Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan, BMC Cardiovascular Disorders, vol.61, issue.12, p.5, 2012. ,
DOI : 10.1002/art.22634
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, J Rheumatol. févr, vol.15, issue.2, pp.202-205, 1988. ,
Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients, Arthritis & Rheumatism, vol.43, issue.2, pp.444-451, 2000. ,
DOI : 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G
Criteria for the classification of early systemic sclerosis, J Rheumatol. juill, vol.28, issue.7, pp.1573-1576, 2001. ,
Management of digital ulcers from systemic scleroderma]. Presse Médicale Paris Fr 1983, févr, vol.37, issue.2 2, pp.271-285, 2008. ,
Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study, Annals of Internal Medicine, vol.120, issue.3, pp.199-206, 1994. ,
DOI : 10.7326/0003-4819-120-3-199402010-00004
Meta-Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis, Arthritis Care & Research, vol.7, issue.Suppl, pp.1460-1471, 2013. ,
DOI : 10.1002/acr.22018
Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients, European Journal of Clinical Pharmacology, vol.53, issue.1, pp.51-56, 1997. ,
DOI : 10.1007/s002280050336
Administration d???iloprost au sein d???une cohorte de 30??patients atteints d???isch??mie digitale??: d??termination de crit??res de bonne tol??rance clinique, La Revue de M??decine Interne, vol.31, p.78, 2010. ,
DOI : 10.1016/j.revmed.2010.03.443
Digital ischemic events related to gemcitabine: Report of two cases and a systematic review, Radiology and Oncology, vol.44, issue.4, pp.257-261, 2010. ,
DOI : 10.2478/v10019-010-0020-1
Acute Hand Ischemia Secondary to Intraarterial Buprenorphine Injection: Treatment with Iloprost and Dextran-40: A Case Report, Angiology, vol.50, issue.7, pp.605-606, 1999. ,
DOI : 10.1177/000331979905000711
Atteintes artérielles des membres supérieurs et inférieurs au cours de la maladie de Horton. Presse Médicale, févr, vol.40, issue.2, pp.151-161, 2011. ,
DOI : 10.1016/j.lpm.2010.11.005
Successful treatment of necrotizing vasculitic lesions after infusion of iloprost in a patient with cryoglobulinemia and chronic HCV infection, Clin Exp Rheumatol. déc, vol.23, issue.6, pp.912-913, 2005. ,
Crise r??nale scl??rodermique, La Presse M??dicale, vol.35, issue.12, pp.1966-74, 2006. ,
DOI : 10.1016/S0755-4982(06)74931-4
Massive pulmonary embolism disclosing thrombocytopenia induced by low molecular weight heparin. Therapeutic success of prostacyclin], Ann Cardiol Angéiologie. déc, vol.40, issue.10, pp.619-621, 1991. ,
Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost, The Journal of Thoracic and Cardiovascular Surgery, vol.127, issue.2, pp.548-554, 2004. ,
DOI : 10.1016/j.jtcvs.2003.08.042
[Treatment of pulmonary arterial hypertension]. Presse Médicale Paris Fr 1983, pp.1445-1455, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-01455600
Attention aux spasmes et thromboses sous iloprost, La Revue de M??decine Interne, vol.29, pp.397-398, 2008. ,
DOI : 10.1016/j.revmed.2008.10.297
Vasoplegic shock and myocardial infarction during administration of iloprost]. Presse Médicale Paris Fr 1983, 23 avr, vol.34, issue.8, pp.585-586, 2005. ,
Cardiovascular risk and prostanoids in systemic sclerosis, Clin Exp Rheumatol. avr, vol.26, issue.2, pp.333-336, 2008. ,
Infacrtus du myocarde sous Iloprost dans la sclérodermie, Rev Med Interne. juin, vol.21, 2000. ,
Systemic Sclerosis Therapy with Iloprost: A Prospective Observational Study of 30 Patients Treated for a Median of 3 Years, Clinical Rheumatology, vol.21, issue.3, pp.244-250, 2002. ,
DOI : 10.1007/PL00011223
Compartment Syndrome as a Rare Complication of Iloprost Infusion for Peripheral Vascular Disease, Annals of Vascular Surgery, vol.25, issue.4, pp.555-566, 2011. ,
DOI : 10.1016/j.avsg.2010.11.012
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions, Pharmacy World and Science, vol.23, issue.3, p.122, 2001. ,
DOI : 10.1023/A:1011231507085
Prostanoids for intermittent claudication, Cochrane Database Syst Rev, vol.5, issue.4, p.986, 2013. ,
DOI : 10.1002/14651858.CD000986.pub3
A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases., Annals of the Rheumatic Diseases, vol.50, issue.11, pp.800-804, 1991. ,
DOI : 10.1136/ard.50.11.800
Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study, J Rheumatol. sept, vol.35, issue.9, pp.1830-1837, 2008. ,
Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group, VASA Z Für Gefässkrankheiten. févr, vol.27, issue.1, pp.15-19, 1998. ,
Tolerability, safety and efficacy of Iloprost infusion without peristaltic pump in systemic sclerosis, Reumatismo, vol.53, issue.2, pp.140-144, 2001. ,
DOI : 10.4081/reumatismo.2001.140
Treatment of patients with peripheral arterial occlusive disease fontaine stage III and IV with intravenous iloprost: an open study in 900 patients, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.54, issue.5, pp.327-333, 1996. ,
DOI : 10.1016/S0952-3278(96)90046-0
Long-term cyclic intravenous iloprost in systemic sclerosis: clinical experience from a single center, Reumatismo, vol.64, issue.3, pp.158-165, 2012. ,
Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man, European Journal of Clinical Pharmacology, vol.13, issue.9, pp.61-68, 1986. ,
DOI : 10.1007/BF00614197
Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers, European Journal of Clinical Pharmacology, vol.225, issue.21, pp.597-605, 1987. ,
DOI : 10.1007/BF02455995
Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis, Acta Derm Venereol. mai, vol.76, issue.3, pp.236-238, 1996. ,
Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.70, issue.6, pp.503-509, 2004. ,
DOI : 10.1016/j.plefa.2003.10.006
The ILAILL Study: Iloprost as Adjuvant to Surgery for Acute Ischemia of Lower Limbs, Annals of Surgery, vol.244, issue.2, pp.185-193, 2006. ,
DOI : 10.1097/01.sla.0000217555.49001.ca
A randomized trial of iloprost in patients with intermittent claudication, Vascular Medicine, vol.13, issue.1, pp.5-13, 2008. ,
DOI : 10.1177/1358863X07084910